

U.S. Application no. 09/911,703

Docket No. 27693-01008

1644
1644

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Serial No.: 09/911,703

Group Art Unit: 1644

Confirmation No.: 4927

Examiner: R. Schwadron

Filed: 25 July 2001

Applicant: Darrell R. ANDERSON et al.

For: Expression and Use of Anti-CD20 Antibodies

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In compliance with the requirements and provisions of 37 C.F.R. §§ 1.56, 1.97, and 1.98, applicant cites the documents listed on the Form PTO-1449 that accompanies this paper.

Applicant does not represent that a search has been conducted or that the cited documents, copies of which are submitted with this paper, are prior art against the claims in this application.

This disclosure statement is filed before the mailing date of a final Office action under the provisions of 37 C.F.R. § 1.97(c)(2). As indicated on the fee transmittal that accompanies this submission, the Director is requested to charge the requisite fee (\$180), as well as any other fees that may be required to make this submission timely or proper, to our Deposit Account No. 18-1260.

11/02/2005 SZEWDIE1 00000115 181260 09911703

01 FC:1806 180.00 DA


Respectfully submitted,

David L. Fitzgerald, Reg. No. 47,347
Attorney for Biogen Idec Inc.

SIDLEY AUSTIN BROWN & WOOD LLP
1501 K Street, N.W.
Washington, DC 20005

tel. (202) 736-8818
fax (202) 736-8711

November 1, 2005




INFORMATION DISCLOSURE STATEMENT	Docket No. 27693-01008	Application No. 09/911,703
	Applicant(s): ANDERSON, Darrell A.	Examiner: SCHWADRON, Ronald B.
	Filing Date: 7/25/2001	Group Art Unit: 1644

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

B1	Chinn, et al. "Production and characterization of radiolabeled anti-CD20 monoclonal antibody: potential application to treatment of B-cell lymphoma." Proceedings of the American Medical Association for Cancer Research, Volume 33, Abstract 2012, p. 337, 1992.
B2	Classon, et al. "The Primary Structure of the Human Leukocyte Antigen CD37, A Species Homologue of the Rat MRC OC-44 Antigen." The Journal of Experimental Medicine, Volume 169, No. 4, pp. 1497-1502, 1989.
B3	DeNardo, et al. "Requirements for a Treatment Plan in System for Radioimmunotherapy." International Journal of Radiation Oncology Biology Physics, Volume 11, Number 2, pp. 335-348, 1985.
B4	Kaminski, et al. "Radioimmunotherapy (RIT) of Refractory B-Cell Lymphoma with ¹³¹ I-Anti-B1 (Anti-CD20) Antibody: Promising Early Results Using Non-Marrow Ablative Radiation Doses." Blood, Abstract 161, p. 162,
B5	Langmuir, "Radiomunotherapy: Clinical Results and Dosimetric Considerations." Nuclear Medicine and Biology, Volume 19, Number 2, pp. 213-225, 1992.
B6	Larson, et al. "Comparison of Bone Marrow Dosimetry and Toxic Effect of High Dose ¹³¹ I-labeled Monoclonal Antibodies Administered to Man." Nuclear Medicine and Biology, Volume 16, No. 2, pp.153-158, 1989.
B7	Leichner, et al. "Tumor dosimetry in radioimmunotherapy: Methods of calculation for beta particles." Medical Physics, Volume 20, Number 2, Pt.2, pp. 529-534, 1993
B8	Leichner, et al. "Dosimetry and Treatment Planning in Radioimmunotherapy." Frontiers of Radiation Therapy and Oncology, Vol. 24, pp. 109-120, 1990.
B9	Link, et al. "A Unique Antigen on Mature B-Cells Defined by a Monoclonal Antibody." The Journal of Immunology, Vol. 137, No. 9, pp. 3013-3018, 1986.
B10	Macey, et al. "A Treatment Planning Program for Radioimmunotherapy" Frontiers of Radiation Therapy and Oncology, Vol. 24, pp. 123-131, 1990.
B11	Meredith, et al. "Dose Fractionation of Radiolabeled Antibodies in Patients with Metastatic Colon Cancer." Journal of Nuclear Medicine, Volume 33, Number 9, pp. 1648-1653, 1992.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO-A820 (also form PTO-1449) SHEET 1 OF 2	



INFORMATION DISCLOSURE STATEMENT	Docket No. 27693-01008	Application No. 09/911,703
	Inventor(s): ANDERSON, Darrell A.	Examiner: SCHWADRON, Ronald B.
	Filing Date: 7/25/2001	Group Art Unit: 1644

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

B12	Parker, et al. "Radioimmunotherapy of Human B-Cell Lymphoma with ⁹⁰ Y-conjugated Antiidiotype Monoclonal Antibody." Cancer Research, Volume 50, No. 3, pp. 1022s-1028s, 1990.
B13	Pearson, et al. "Enhanced Therapeutic Efficacy of an Immunotoxin in combination with Chemotherapy against an Intraperitoneal Human Tumor Xenograft in Athymic Mice." Cancer Research Volume 49, No. 18, pp. 4990-4995, 1989.
B14	Press, et al. "Endocytosis and Degradation of Monoclonal of Antibodies Targeting Human B-Cell Malignancies" Cancer Research, Volume 49, No. 17, pp. 4906-4912, 1989.
B15	Press, et al. "Radiolabeled Antibody Therapy of Human B Cell Lymphomas." Immunobiology of Proteins and Peptides VI, Volume 303, pp. 91-96, 1991.
B16	Securities and Exchange Commission, Form S-1 Registration Statement, Filed 1991, IDEC Pharmaceuticals
B17	Senter, Peter D. "Activation of prodrugs by antibody-enzyme conjugates: a new approach to cancer therapy." The FASEB Journal, Vol. 4. pp. 188-193, 1990.
B18	Senter, et al. "Activation of Prodrugs by Antibody-Enzyme Conjugates" Immunobiology of Proteins and Peptides VI, Volume 303, pp. 97-105, 1991.
B19	Schwartz-Albiez, et al. "The B Cell-Associated CD37 Antigen (gp40-52) Structure and Subcellular Expression of an Extensively Glycosylated Glycoprotein." The Journal of Immunology, Vol. 140, No. 3, pp. 905-914, 1988.
B20	Sharkey, et al. "Biological Considerations for Radioimmunotherapy." Cancer Research, Volume 50, No. 3, pp. 964s-969s, pp. 1990.
B21	Stewart, et al. "Intraperitoneal ¹³¹ I- And ⁹⁰ Y-Labelled Monoclonal Antibodies for Ovarian Cancer: Pharmacokinetics and Normal Tissue Dosimetry." International Journal of Cancer, Supplement 3, pp. 71-76, 1988.
B22	Uckun, et al. "Combined Ex Vivo Treatment with Immunotoxins and Mafosfamid: A Novel Immunochemotherapeutic Approach for Elimination of Neoplastic T Cells from Autologous Marrow Grafts." The Journal of Immunology, Vol. 134, No. 5, pp. 3504-3515, 1985.
B23	Uckun, et al. "Increased Efficiency in Selective Elimination of Leukemia Cells by a Combination of a Stable Derivative of Cyclophosphamide and a Human B-Cell-specific Immunotoxin Containing Pokeweed Antiviral Protein." Cancer Research, Volume 45, No. 1, pp. 69-75, 1985.
B24	Yokota, et al. "Synergistic Potentiation of in Vivo Antitumor Activity of Anti-Human T-Leukemia Immunotoxins by Recombinant α -Interferon and Daunorubicin." Cancer Research, Volume 50, No. 1, pp. 32-37, 1990.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO-A820 (also form PTO-1449)	
SHEET 2 OF 2	